Image Source: TransCure bioServices
According to a newly published report, the worldwide Humanized Mouse and Rat Model Market will reach US$409.8 million by 2030, growing at a healthy 8.2% CAGR from a 2024 valuation of US$255.8 million. The growth of the Humanized Mouse and Rat Model Market will be driven by the increasing use of humanized animal models in drug discovery, demand for personalized medicine, and increasing R&D efforts in the pharmaceutical and biotechnology industries.
Humanized Mouse Models, primarily from advanced genetic engineering technologies, will dominate the market, accounting for the largest share of revenue in 2024 and will continue to do so during the forecast period. Humanized mouse models are used to study drug metabolism and immune system development and evaluate the safety and efficacy of new therapeutics. Oncology remains the largest application segment due to the increase in cancer research and development funding from the government.
The end-users of humanized mouse and rat models primarily include pharmaceutical and biotechnology companies for preclinical research in immuno-oncology, cell and gene therapy, and biologics. Contract research organizations (CROs) and academic institutes also represent significant segments of the market, often procuring products, models, and services from organizations like Taconic Biosciences, The Jackson Laboratory, and Hera BioLabs.
Geographically, North America leads the market, but the fastest growing region will be the Asia Pacific, owing to increased R&D activities, a growing pharmaceutical industry, and an uptick in outsourcing preclinical and clinical research services to CROs in China and India.
Key players profiled in the report include Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, JSR Corporation (Crown Biosciences), Champions Oncology, CLEA Japan, genOway, Inotiv, Janvier Labs, Altogen Labs, Vitalstar Biotechnology, Ingenious Targeting Laboratory, Reaction Biology, Harbour BioMed, Oncodesign Services, Pharmatest Services, Ozgene Pty Ltd., TransCure bioServices, Cyagen Biosciences, Aragen Life Sciences, GemPharmatech, and Biocytogen.
Growing demand for humanized mouse models and rat models is supported by technological and genetic engineering advances, the moves towards more CRISPR utilization, and the increasing popularity of patient derived xenograft (PDX) . At the same time, there are challenges from alternative testing methods and increasing scrutiny around the use of humanized que model systems by regulatory agencies.
Source: PR Newswire
Advertisement
Advertisement
